Ropeginterferon alfa-2b

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera

Conditions

Polycythemia Vera

Trial Timeline

Oct 8, 2021 → Jul 1, 2027

NCT ID

NCT05485948

About Ropeginterferon alfa-2b

Ropeginterferon alfa-2b is a phase 2 stage product being developed by PharmaEssentia for Polycythemia Vera. The current trial status is active. This product is registered under clinical trial identifier NCT05485948. Target conditions include Polycythemia Vera.

What happened to similar drugs?

2 of 17 similar drugs in Polycythemia Vera were approved

Approved (2) Terminated (1) Active (15)

✅HydroxyureaNovartisApproved

✅Ropeginterferon alfa-2bPharmaEssentiaApproved

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07468916	Phase 2	Recruiting	Mar 29, 2026	Mar 30, 2032	Atypical Chronic Myeloid Leukemia
NCT06290765	Approved	Recruiting	Feb 1, 2026	Jun 30, 2027	Polycythemia Vera
NCT07047885	Phase 1	Recruiting	Aug 27, 2025	Jun 1, 2028	Cutaneous T Cell Lymphoma
NCT06468033	Phase 3	Recruiting	Jul 18, 2025	Sep 30, 2028	Primary Myelofibrosis
NCT05485948	Phase 2	Active	Oct 8, 2021	Jul 1, 2027	Polycythemia Vera
NCT03546465	Phase 1	Completed	May 7, 2018	Jul 15, 2019	Healthy Volunteers

Competing Products

20 competing products in Polycythemia Vera

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	47
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Ruxolitinib + BAT	Novartis	Phase 2	39
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
Smac Mimetic LCL161	Novartis	Phase 2	35
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	40
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	35
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	47